Biopharma news

Here are 60 Best Pharma News Websites you must follow in 2024. 1. BioWorld. BioWorld is biopharma's trusted news source, offering breaking news and analysis of the global biotechnology, pharmaceutical, medical device, and medical technology...
Trends
The OK for mResvia adds another option for preventing RSV-related disease in older adults, one year after the agency cleared shots from GSK and Pfizer. BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover...
Top Pharma Blogs & Websites For BioPharma in 2024. We've put together a collection of the top sites, blogs, and forums to keep you up to date on everything in the pharmaceutical industry, from clinical trials, mergers and acquisitions, and drug...
  • Safe
  • Encrypted

Nov 13, 2023 05:00am. See more articles. Fierce Pharma delivers breaking news and analysis about drug companies, the FDA and the broader pharma industry, including manufacturing, marketing and ...
6/12/2024. The North America active pharmaceutical ingredients market size was USD 91.60 billion in 2023, calculated at USD 96.00 billion in 2024 and is expected to reach around USD 146.39 billion by 2033, expanding at a CAGR of 4.8% from 2024 to 2033....
BioXcel Reports Positive OS Data From Phase 2 Trial of BXCL701 in Patients with SCNC. On October 10, 2023 By Justin Volpe Cancer Clinical Trials Prostate Cancer Small Molecules. In the trial, evaluable patients with SCNC as of a data cutoff of September...
  • Safe
  • Encrypted

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on Fierce Biotech as their must-read source for the latest news, analysis and data in the world of biotech ...
Arrivent, Alphamab ink $615.5M multitarget ADC partnership. Arrivent Biopharma Inc. and Jiangsu Alphamab Biopharmaceuticals Co. Ltd. have signed a development deal that leverages Alphamab's antibody-drug conjugate (ADC) research and... More in...
13 May, 2024 | Monday | Company results. Bio-Rad's CEO, Norman Schwartz, Finds Hope in Adversity: "Our Vision Remains Strong Despite Market Challenges". First-quarter 2024 total net sales were $610.8 million, a decrease of 9.8 percent...
  • Safe
  • Encrypted

Biogen, Ionis to discontinue development of experimental ALS drug. May 16, 2024. The latest international Biopharma news and views from Reuters - one of the world's largest news agencies.
See more